Cargando…

A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma

BACKGROUND: Hematogenous metastasis is essential for the progression of advanced hepatocellular carcinoma (HCC) and can occur even after patients receive multidisciplinary therapies, including immunotherapy and hepatectomy; circulating tumor cells (CTCs) are one of the dominant components of the met...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xiu-Yan, Li, Feng, Li, Ting-Ting, Zhang, Jun-Tao, Shi, Xiang-Jun, Huang, Xin-Yu, Zhou, Jian, Tang, Zhao-You, Huang, Zi-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867854/
https://www.ncbi.nlm.nih.gov/pubmed/36681851
http://dx.doi.org/10.1186/s12951-023-01783-9
_version_ 1784876429444382720
author Huang, Xiu-Yan
Li, Feng
Li, Ting-Ting
Zhang, Jun-Tao
Shi, Xiang-Jun
Huang, Xin-Yu
Zhou, Jian
Tang, Zhao-You
Huang, Zi-Li
author_facet Huang, Xiu-Yan
Li, Feng
Li, Ting-Ting
Zhang, Jun-Tao
Shi, Xiang-Jun
Huang, Xin-Yu
Zhou, Jian
Tang, Zhao-You
Huang, Zi-Li
author_sort Huang, Xiu-Yan
collection PubMed
description BACKGROUND: Hematogenous metastasis is essential for the progression of advanced hepatocellular carcinoma (HCC) and can occur even after patients receive multidisciplinary therapies, including immunotherapy and hepatectomy; circulating tumor cells (CTCs) are one of the dominant components of the metastatic cascade. However, the CTC capture efficiency for HCC is low due to the low sensitivity of the detection method. In this study, epithelial cell adhesion molecule (EpCAM)/vimentin/Glypican-3 (GPC3) antibody-modified lipid magnetic spheres (LMS) were used to capture tumor cells with epithelial phenotype, mesenchymal phenotype and GPC3 phenotype, respectively, in order to capture more CTCs with a more comprehensive phenotype for monitoring tumor metastasis. RESULTS: The novel CTC detection system of Ep-LMS/Vi-LMS/GPC3-LMS was characterized by low toxicity, strong specificity (96.94%), high sensitivity (98.12%) and high capture efficiency (98.64%) in vitro. A sudden increase in CTC counts accompanied by the occurrence of lung metastasis was found in vivo, which was further validated by a clinical study. During follow-up, the rapid increase in CTCs predicted tumor progression in HCC patients. Additionally, genetic testing results showed common genetic alterations in primary tumors, CTCs and metastatic tissues. The proportion of patients predicted to benefit from immunotherapy with the CTC detection method was higher than that for the tissue detection method (76.47% vs. 41.18%, P = 0.037), guiding the application of clinical individualized therapy. CONCLUSIONS: The Ep-LMS/Vi-LMS/GPC3-LMS sequential CTC capture system is convenient and feasible for the clinical prediction of HCC progression. CTCs captured by this system could be used as a suitable alternative to HCC tissue detection in guiding immunotherapy, supporting the clinical application of CTC liquid biopsy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-023-01783-9.
format Online
Article
Text
id pubmed-9867854
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98678542023-01-23 A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma Huang, Xiu-Yan Li, Feng Li, Ting-Ting Zhang, Jun-Tao Shi, Xiang-Jun Huang, Xin-Yu Zhou, Jian Tang, Zhao-You Huang, Zi-Li J Nanobiotechnology Research BACKGROUND: Hematogenous metastasis is essential for the progression of advanced hepatocellular carcinoma (HCC) and can occur even after patients receive multidisciplinary therapies, including immunotherapy and hepatectomy; circulating tumor cells (CTCs) are one of the dominant components of the metastatic cascade. However, the CTC capture efficiency for HCC is low due to the low sensitivity of the detection method. In this study, epithelial cell adhesion molecule (EpCAM)/vimentin/Glypican-3 (GPC3) antibody-modified lipid magnetic spheres (LMS) were used to capture tumor cells with epithelial phenotype, mesenchymal phenotype and GPC3 phenotype, respectively, in order to capture more CTCs with a more comprehensive phenotype for monitoring tumor metastasis. RESULTS: The novel CTC detection system of Ep-LMS/Vi-LMS/GPC3-LMS was characterized by low toxicity, strong specificity (96.94%), high sensitivity (98.12%) and high capture efficiency (98.64%) in vitro. A sudden increase in CTC counts accompanied by the occurrence of lung metastasis was found in vivo, which was further validated by a clinical study. During follow-up, the rapid increase in CTCs predicted tumor progression in HCC patients. Additionally, genetic testing results showed common genetic alterations in primary tumors, CTCs and metastatic tissues. The proportion of patients predicted to benefit from immunotherapy with the CTC detection method was higher than that for the tissue detection method (76.47% vs. 41.18%, P = 0.037), guiding the application of clinical individualized therapy. CONCLUSIONS: The Ep-LMS/Vi-LMS/GPC3-LMS sequential CTC capture system is convenient and feasible for the clinical prediction of HCC progression. CTCs captured by this system could be used as a suitable alternative to HCC tissue detection in guiding immunotherapy, supporting the clinical application of CTC liquid biopsy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-023-01783-9. BioMed Central 2023-01-21 /pmc/articles/PMC9867854/ /pubmed/36681851 http://dx.doi.org/10.1186/s12951-023-01783-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Huang, Xiu-Yan
Li, Feng
Li, Ting-Ting
Zhang, Jun-Tao
Shi, Xiang-Jun
Huang, Xin-Yu
Zhou, Jian
Tang, Zhao-You
Huang, Zi-Li
A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma
title A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma
title_full A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma
title_fullStr A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma
title_full_unstemmed A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma
title_short A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma
title_sort clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867854/
https://www.ncbi.nlm.nih.gov/pubmed/36681851
http://dx.doi.org/10.1186/s12951-023-01783-9
work_keys_str_mv AT huangxiuyan aclinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma
AT lifeng aclinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma
AT litingting aclinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma
AT zhangjuntao aclinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma
AT shixiangjun aclinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma
AT huangxinyu aclinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma
AT zhoujian aclinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma
AT tangzhaoyou aclinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma
AT huangzili aclinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma
AT huangxiuyan clinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma
AT lifeng clinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma
AT litingting clinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma
AT zhangjuntao clinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma
AT shixiangjun clinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma
AT huangxinyu clinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma
AT zhoujian clinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma
AT tangzhaoyou clinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma
AT huangzili clinicallyfeasiblecirculatingtumorcellsortingsystemformonitoringtheprogressionofadvancedhepatocellularcarcinoma